Pfizer is requesting proposals for PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape.
Donor Name: Pfizer
State: All States
County: All Counties
Type of Grant: Grant
Deadline: 08/21/2025
Size of the Grant: $100,000 to $500,000
Grant Duration: 2 Years
Details:
Areas of Interest
Projects that will be considered for Pfizer support will focus on increasing healthcare professional knowledge and competence in the following areas:
- Guideline concordance and best practices for integration of testing into clinical practice, including: when to order testing and how to interpret results of biomarkers and genetic mutations (inclusive of all HRR mutations, i.e. BRCA and non-BRCA), the role of the multidisciplinary team in ordering tests, and education on strategies to identify and remove barriers to appropriate testing for patients with prostate cancer.
- Emerging data on efficacy and safety regarding PARPi’s used in the treatment of mPC including better understanding of: 1) the mechanism of action and the biological and clinical rationale for PARPi combinations and; 2) clinical safety, treatment sequencing and patient subgroup data.
- Clinical data regarding PARPi combinations and how to mitigate associated side effects for optimal patient care, including but not limited to, the role of the multidisciplinary team in ongoing therapy management.
- Best practices for initiating guideline concordant care for patients with mPC in community healthcare settings for optimal therapy management of PARPi combinations in prostate cancer including but not limited to, implementation of genetic testing workflows and encouraging patient engagement in treatment decisions and clinical trial participation.
Examples of educational formats that will be considered under this RFP include but are not limited to:
- On-agenda educational sessions during live conferences
- Multi-company supported, stand-alone symposia
- Expert interviews recorded at live conferences, conference coverage reviews
- Online articles, newsletter articles, training courses, webinars
- Social media posted & linked content
- Videos, podcasts, infographics, animations.
Funding Information
Individual projects requesting up to $350,000 will be considered. The estimated total available budget related to this RFP is $850,000. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. Multi-supported educational programs encouraged.
Grant Period
October 2025 to April 2027 (18 months preferred maximum length; projects may be shorter than 18 months).
Target Audience
Community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, genetic counselors, and other healthcare professionals involved in the care and treatment of patients with mCRPC.
Eligibility Criteria
- Applicant organizations to this RFP must be based in the United States.
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- For projects offering continuing education credit in the United States, the requesting organization must be accredited.
For more information, visit Pfizer.
